CLCD News

14 companies were scheduled to go public this week, including 10 health care deals. Only 8 IPOs got through, as 3 biotechs have been pushed back to next week, two companies postponed and one withdrew. however; IPO investors had plenty of options while the NASDAQ composite hit a 1-month low. This week's deals did include the year's largest IPO so far and the first restaurant chain...read more

CoLucid Pharmaceuticals, a late-stage biotech developing therapies for acute migraines, raised $55 million by offering 5.5 million shares at $10, below its original $13 to $15 range. The company increased the shares offered, dropped the IPO price to $10 and increased insider buying to $25 million (45% of the deal) in an amendment filed with the SEC on Monday. ...read more

CoLucid Pharmaceuticals, a late-stage biotech developing therapies for acute migraines, lowered the proposed deal size and valuation for its upcoming IPO on Tuesday. The Burlington, MA-based company now plans to raise $55 million by offering 5.5 million shares for $10 each. It had previously filed to offer 5.36 million shares at a range of $13 to $15. At the revised price,...read more

This could be the busiest 5-day stretch in the IPO market since the week of July 28, 2014, as 14 companies look to raise nearly $2 billion. However, last week's mediocre returns suggest that ...read more